TrialNeurology2008
Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.
E J Sorenson et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
105 papers cite itlatest 60 shown
this paperpooled ittrialcites it
TrialNeurology2008
E J Sorenson et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.